Policy14 min

Global Legalization: Where We Stand in 2026

From Canada to Germany, Uruguay to the Czech Republic — the countries, the models, the results, and why the UK lags behind.

The global cannabis landscape in 2026 bears almost no resemblance to the one that existed a decade ago. In 2016, only two countries — Uruguay and Canada — had legalised cannabis for adult use. Today, nearly 50 countries have legalised cannabis for medical use, and a growing vanguard has legalised recreational adult use under varying regulatory models. A reform wave that once seemed improbable is now unmistakable. [MPP (2026)]

Countries That Have Legalised

Canada (2018): The first major G7 industrial nation to completely legalise, regulate, and commercialise adult-use recreational cannabis nationwide via the Cannabis Act (Bill C-45). Provinces control retail distribution, marketing is strictly limited, and a federal excise tax funds addiction research and public education. Results: illegal market participation has fallen by an estimated 70%, youth use has not increased, and opioid overdose deaths in provinces with legal cannabis access have declined modestly but significantly. [Cannabis Europa]

Uruguay (2013): The first country in the world to fully legalise recreational cannabis. The state-controlled model uses licensed pharmacies for distribution with a registry system, permits home cultivation, and operates cannabis clubs. Registered users can purchase up to 40g per month. The model deliberately avoids commercial marketing and branding, resulting in a functional but unglamorous market with no corporate advertising and a steady reduction in drug-related incarceration.

Germany (2024): Enacted the Cannabisgesetz (CanG), permitting adults to possess up to 25g in public, grow up to three plants at home, and distribute cannabis via non-profit Cannabis Social Clubs capped at 500 members. The model deliberately avoids the corporate consolidation seen in North America, prioritising social equity over market scale. Early data suggests consumption patterns have shifted from street purchases to club-sourced product. [Cannabis Europa]

The Czech Republic (2026): Implemented comprehensive personal legalisation on January 1, 2026, legalising possession of up to 25g in public, 100g at home, and home cultivation of up to three plants.

Malta (2021) & Luxembourg (2023): Both legalised personal home cultivation and small-scale possession through non-profit association structures. Malta caps membership at 500 and prohibits advertising entirely.

South Africa & Georgia: Both legalised private, adult personal use and cultivation following landmark rulings by their respective Constitutional Courts, which determined that criminalising private possession violated constitutional privacy rights.

United States: 24 States and Counting

Because cannabis remains classified as a federal Schedule I controlled substance, legalisation has played out subnationally. As of 2026, 24 states, the District of Columbia, and three U.S. territories (Guam, the Northern Mariana Islands, and the U.S. Virgin Islands) have fully legalised adult-use recreational cannabis. The 24 states are: Colorado, Washington, Alaska, Oregon, California, Nevada, Massachusetts, Maine, Vermont, Michigan, Illinois, New Jersey, Montana, New York, Virginia, New Mexico, Connecticut, Rhode Island, Maryland, Missouri, Delaware, Minnesota, Ohio, and South Dakota. [MPP (2026)]

This creates a profound federal-state contradiction: state-licensed businesses cannot access banking services, deduct ordinary business expenses from federal tax, or transport products across state lines. Public opinion — tracked by YouGov at 68% support for full legalisation — has far outpaced federal action. [YouGov Tracker]

24 US states, DC, and 3 territories have legalised cannabis. Yet it remains a Schedule I federal substance — a contradiction that creates extraordinary practical difficulties.

The Drivers of Legalisation

The push for legalisation is the result of decades of targeted public policy battles led by distinct coalitions. The core reasons fall into three categories:

Economic and Fiscal Yield: Governments recognise that the illegal market generates billions in untaxed revenue. Legalised markets shift these funds to the state via excise taxes, generating billions to fund public schools, infrastructure, and healthcare.

Dismantling Criminal Syndicates: Legal frameworks remove a primary revenue stream from organised crime networks, transferring quality control and distribution to licensed, tax-paying businesses.

Racial and Social Justice: In the United States, enforcement of cannabis prohibition disproportionately targeted Black and Hispanic communities despite equal usage rates across demographics. Legalisation campaigns emphasise expungement of criminal records and social equity licensing.

Key advocacy organisations include NORML (National Organization for the Reform of Marijuana Laws) and the Marijuana Policy Project (MPP) in the U.S., alongside Drug Science and Transform Drug Policy Foundation in the UK. Prominent political leaders include Canadian Prime Minister Justin Trudeau, who ran on an explicit 2015 campaign promise to legalise, and German Health Minister Karl Lauterbach, who successfully navigated EU regulatory hurdles to pass the 2024 reform bill.

Why Some Countries Lag Behind

The 1961 UN Single Convention on Narcotic Drugs mandates that signatory nations criminalise cannabis for non-medical purposes. Many risk-averse governments lag behind to avoid the diplomatic friction or potential economic sanctions tied to violating international treaties. In many democracies, older, high-turnout voting demographics — raised on 20th-century anti-drug campaigns — view cannabis through a lens of moral panic, making reform politically risky. In parts of East Asia (Japan, South Korea) and the Middle East, drug policies remain deeply zero-tolerance, driven by collectivist cultural norms.

The United Kingdom: A Policy Paradox

The UK presents a glaring contradiction. While the Home Office maintains strict domestic prohibition treating recreational cannabis as a Class B criminal drug, the UK has simultaneously functioned as one of the largest producers and exporters of legal, pharmaceutical-grade medical cannabis in the world. GW Pharmaceuticals (acquired by Jazz Pharmaceuticals in 2021 for $7.2 billion) developed Sativex and Epidiolex — highly profitable, cannabis-derived medications exported globally. This created a state-sanctioned monopoly on a plant that ordinary British citizens are jailed for growing in their gardens. [Left Foot Forward (2021)]

The contradictions run deep. Victoria Atkins served as a Home Office Minister with a brief that included drug policy while her husband, Paul Kenward, was Managing Director of British Sugar — which, under an exclusive Home Office license, cultivated tons of medical cannabis for GW Pharmaceuticals in Norfolk. Following public outcry regarding "hypocrisy on a grand scale," Atkins was forced to recuse herself from speaking for the government on cannabis policy. Meanwhile, Philip May — husband of former Prime Minister Theresa May — worked for Capital Group, the single largest institutional shareholder in GW Pharmaceuticals, directly profiting from the global expansion of the UK's legal medical cannabis export monopoly while his wife's government maintained strict prohibition at home. [The Independent (2018)]

Neither the Conservative Party nor the Labour Party supports recreational legalisation, calculating that reform risks alienating older, socially conservative swing voters. While medical cannabis was technically legalised in the UK in November 2018, the NHS restricts prescribing to an absolute minimum — over 1.4 million patients are priced out and forced to turn to the illicit black market.

The UK is one of the world's largest producers and exporters of medical cannabis — while jailing its own citizens for growing the exact same plant.

The 2026 MCDA harm scores tell the full story: alcohol scores 79 out of 100, cannabis scores 15. The direction of global travel is clear — as more countries legalise and the data from their experiences accumulates, the argument for reform becomes harder to resist. Explore our legalisation page for the full legal analysis.